Journal Mobile Options
Table of Contents
Vol. 57, No. 5, 2013
Issue release date: September – October
Section title: Techniques
Acta Cytologica 2013;57:501-508
(DOI:10.1159/000351475)

Phosphohistone H3 and Ki-67 Labeling Indices in Cytologic Specimens from Well-Differentiated Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas: A Comparative Analysis Using Automated Image Cytometry

Fung A.D. · Cohen C. · Kavuri S. · Lawson D. · Gao X. · Reid M.D.
aDepartment of Pathology, Emory University School of Medicine, Atlanta, Ga., and bDepartment of Pathology, Georgia Health Sciences University, Augusta, Ga., USA

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Abstract

Background: Ki-67 proliferation index was recently incorporated in the grading of neuroendocrine neoplasms (NENs) of the gastrointestinal tract (GIT) and pancreas. These are now divided into well-differentiated neuroendocrine tumors (WDNETs, grades 1 and 2) and poorly differentiated neuroendocrine carcinomas (grade 3). While Ki-67 is an established proliferation marker in NENs, phosphohistone H3 (PHH3), a newer marker of mitotic activity, is not. Methods: We determined Ki-67 and PHH3 indices on cytologic samples from WDNETs of the GIT and pancreas using an automated cellular imaging system (ACIS®). Results: There was a strong correlation between Ki-67 and PHH3 indices generated by ACIS on cytologic samples. However, in some cases the two stains caused conflicting grades within the same tumor. Conclusion: Both antibodies stain cells in different phases of the cell cycle which may cause discordant grades, thus affecting patient management and prognostication. Ki-67 staining is stronger than PHH3, making ‘hot spots' easier to identify on ACIS. Ki-67 is more ideal than PHH3 for staining NENs, especially in tumors with borderline grades. Because PHH3 generates lower mitotic indices it should not be used as a proliferation marker in NENs until its expression has been further characterized.


Article / Publication Details

First-Page Preview
Abstract of Techniques

Received: 4/2/2013
Accepted: 4/18/2013
Published online: 9/7/2013

Number of Print Pages: 8
Number of Figures: 4
Number of Tables: 4

ISSN: 0001-5547 (Print)
eISSN: 1938-2650 (Online)

For additional information: http://www.karger.com/ACY


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.